Should You Continue to Hold Hologic Stock Post Q4 Earnings?
HOLX's solid Q4 growth and a pending $18.3B buyout sharpen its focus as the company prepares to end its publicly traded chapter.
Qiagen ( QGEN ) International Revenue in Focus: Trends and Expectations
Evaluate Qiagen's (QGEN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Hologic Expands European Reach of Genius Digital Diagnostics System
HOLX gains expanded CE marking for its Genius Digital Diagnostics System, enabling imaging of both cell and tissue specimens on one platform.
Why Qiagen ( QGEN ) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Qiagen ( QGEN ) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool.Wednesday, November 5, 2025 at 9:30 a.m. ETChief Executive Officer - Thierry BernardContinue reading ...
Qiagen ( QGEN ) Q3 Earnings and Revenues Surpass Estimates
Qiagen (QGEN) delivered earnings and revenue surprises of +5.17% and +1.25%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Cytokinetics ( CYTK ) Q3 Earnings Expected to Decline
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Qiagen ( QGEN ) to Report a Decline in Earnings: What to Look Out for
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PacBio Aims to Expand Multiomic Capabilities Via Latest Innovations
PACB unveils new SPRQ-Nx chemistry to cut sequencing costs and boost multiomic features on Revio and Vega.
Will Positive Regulatory Updates Further Boost INCY Stock?
Incyte's strong 2025 performance is fueled by Jakafi's sustained growth and label expansion of Opzelura.
Oculis Holding AG ( OCS ) Soars 6.3%: Is Further Upside Left in the Stock?
Oculis Holding AG (OCS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
QGEN vs. ACAD: Which Stock Is the Better Value Option?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Qiagen ( QGEN Quick QuoteQGEN - ) and Acadia Pharmaceuticals ( ACAD Quick QuoteACAD - ) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
Hologic Expands Panther Fusion's Menu With Diagnostic Innovation
HOLX expands its Panther Fusion platform with new GI bacterial assays, securing FDA and EU approvals to boost Diagnostics growth.
How to Play HOLX Stock This Breast Cancer Awareness Month?
Hologic's breast health innovations, AI breakthroughs and leadership moves signal optimism ahead despite macro headwinds.
Illumina to Join Pharma Partners for CDx Development on KRAS Biomarker
ILMN partners with pharma leaders to advance KRAS-focused companion diagnostics through its TruSight Oncology platform.
Quest Diagnostics Joins Forces With Epic to Improve Laboratory Testing
DGX teams up with Epic on Project Nova to streamline lab testing, boost efficiency, and enhance patient and provider experiences.
PacBio Enters Carrier Screening Market With PureTarget Expansion
PACB expands its PureTarget portfolio, streamlining carrier screening with HiFi sequencing to meet rising global demand.
QuidelOrtho Expands Portfolio With the Launch of FDA-Approved Test
QDEL boosts its respiratory testing lineup with the FDA-cleared QUICKVUE Influenza + SARS Test for professional use.
DGX's Haystack Oncology Teams Up With Rutgers Cancer Institute
Quest Diagnostics' Haystack Oncology joins Rutgers Cancer Institute to study how its ctDNA MRD test can guide therapy for stage II/III lung cancer.
Tempus AI Enhances Cancer Research Tools With FDA-Cleared xR IVD
TEM secures FDA clearance for its xR IVD device, advancing RNA-based cancer research and precision medicine tools.
INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream
Incyte secures FDA nod for Opzeluras pediatric use in atopic dermatitis, marking its third U.S. approval and boosting sales momentum.
QGEN Stock Gains From CE-IVDR Certification for QIAstat-Dx Portfolio
QIAGEN secures CE-IVDR certification for its full QIAstat-Dx portfolio, boosting its diagnostics arm and lifting shares.
Hologic's 2025 Outlook Improves on Strong Q3, Easing Tariff Headwinds
HOLX lifts its 2025 revenue and EPS outlook on Q3 strength, tariff relief, and growth across Breast Health and GYN Surgical.
QIAGEN Stock May Benefit From the US Clearance of QIAstat-Dx Rise
QGEN announces the launch of FDA-cleared QIAstat-Dx Rise, which may boost U.S. diagnostic access and testing capacity worldwide.
The Role of M&A in Hologic's Growth Story: Are More Deals in Sight?
HOLX fuels growth with targeted M&A across Diagnostics, Breast Health, and GYN Surgical, backed by a strong balance sheet.
Biobanking Market is expected to generate a revenue of USD 2.11 Billion by 2031, Globally, at 9.89% CAGR: Verified Market Research®
Lewes, Delaware, Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- The Global Biobanking Market Size is projected to grow at a CAGR of 9.89% from 2024 to 2031, according to a new report published by Verified Market Research®.
INCY Stock Trading Close to Its 52-Week High: Buy, Sell or Hold?
Incyte hits a fresh 52-week high on strong Jakafi and Opzelura sales, pipeline wins and upbeat investor sentiment.
Veterinary Diagnostics Market is expected to generate a revenue of USD 4.52 Billion by 2031, Globally, at 6.59% CAGR: Verified Market Research®
Lewes, Delaware, Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- The Global Veterinary Diagnostics Market Size is projected to grow at a CAGR of 6.59% from 2024 to 2031, according to a new report published by Verified Market Research®.
Why Qiagen ( QGEN ) International Revenue Trends Deserve Your Attention
Examine the evolution of Qiagen's (QGEN) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Baculovirus Expression System Market Poised for Significant Growth, Estimate to Hit USD 781.8 Million by 2032 | Coherent Market Insights
Burlingame, CA, Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- The global Baculovirus Expression System Market is estimated to be valued at USD 436.0 Mn in 2025 and is expected to reach USD 781.8 Mn in 2032, exhibiting a compound annual growth rate ( CAGR ) of 8.7% from 2025 to 2032.
DoorDash To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday - AppLovin ( NASDAQ:APP ) , Crocs ( NASDAQ:CROX )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. UBS raised Qiagen N.V. QGEN price target from $48 to $50. UBS analyst John Sourbeer maintained a Neutral ...
Qiagen ( QGEN ) Matches Q2 Earnings Estimates
Qiagen (QGEN) delivered earnings and revenue surprises of 0.00% and +1.80%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
CERVOMED INC ( CRVO ) Surges 11.6%: Is This an Indication of Further Gains?
CERVOMED INC (CRVO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Why Qiagen ( QGEN ) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is Hologic Stock a Risky Investment Ahead of Its Q3 Earnings Report?
HOLX heads into Q3 earnings with revenue and EPS estimates down, tariff pressures mounting, and stock lagging peers.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
QGEN or EXAS: Which Is the Better Value Stock Right Now?
QGEN vs. EXAS: Which Stock Is the Better Value Option?
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is Hologic Stock's Low Valuation an Opportunity or a Value Trap?
HOLX trades below peers on P/S, but falling EPS, weak Breast Health sales and China risks cloud the outlook.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock?
INCY stock climbs 9.2% in three months as FDA approvals and a new diagnostic deal fuel pipeline momentum.
QGEN vs. EXAS: Which Stock Is the Better Value Option?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Qiagen ( QGEN Quick QuoteQGEN - ) and Exact Sciences ( EXAS Quick QuoteEXAS - ) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
Qiagen ( QGEN ) Just Flashed Golden Cross Signal: Do You Buy?
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
Exosome Research Market is expected to generate a revenue of USD 646.52 Million by 2032, Globally, at 13.93% CAGR: Verified Market Research®
Lewes, Delaware, June 19, 2025 ( GLOBE NEWSWIRE ) -- The Global Exosome Research Market Size is projected to grow at a CAGR of 13.93% from 2026 to 2032, according to a new report published by Verified Market Research®.
QIAGEN's New QIAcuity dPCR IVD Pact With GENCURIX May Boost Its Stock
QGEN teams with GENCURIX to expand its digital PCR IVD offerings, aiming to strengthen its precision diagnostics arm.
Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics
INCY jumps 5.1% on a global QIAGEN deal to develop a companion diagnostic for its mutCALR-targeting cancer therapy.
QGEN Stock Rises in After Market Following Partnership With Incyte
QIAGEN teams up with Incyte to develop NGS-based companion diagnostics for blood cancers.
Why Incyte Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket - Battalion Oil ( AMEX:BATL ) , AIRO Group Holdings ( NASDAQ:AIRO )
Shares of Incyte Corporation INCY rose sharply in today's pre-market trading. QIAGEN and Incyte disclosed a precision medicine collaboration to develop companion diagnostics for patients with mutant CALR-expressing Myeloproliferative Neoplasms ( MPNs ) .
Should You Add QIAGEN Stock to Your Portfolio for Now?
QGEN rides on test menu growth, strategic partnerships, and strong solvency, despite macro and market headwinds.
Genomics Market to Hit US$66.8 Billion by 2029 with 9.4% CAGR | MarketsandMarkets™.
Delray Beach, FL, June 11, 2025 ( GLOBE NEWSWIRE ) -- The global genomics market, valued at US$42.4 billion in 2023, stood at US$42.6 billion in 2024 and is projected to advance at a resilient CAGR of 9.4% from 2024 to 2029, culminating in a forecasted valuation of US$66.8 billion by the end of ...
